Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Entrada Therapeutics (TRDA) EBITDA (2022 - 2025)

Entrada Therapeutics has reported EBITDA over the past 4 years, most recently at -$39.1 million for Q4 2025.

  • Quarterly results put EBITDA at -$39.1 million for Q4 2025, down 33835.34% from a year ago — trailing twelve months through Dec 2025 was -$143.1 million (down 318.78% YoY), and the annual figure for FY2025 was -$143.1 million, down 318.78%.
  • EBITDA for Q4 2025 was -$39.1 million at Entrada Therapeutics, up from -$43.9 million in the prior quarter.
  • Over the last five years, EBITDA for TRDA hit a ceiling of $54.9 million in Q2 2024 and a floor of -$43.9 million in Q3 2025.
  • Median EBITDA over the past 4 years was -$20.0 million (2022), compared with a mean of -$11.2 million.
  • Biggest five-year swings in EBITDA: surged 538.39% in 2024 and later plummeted 33835.34% in 2025.
  • Entrada Therapeutics' EBITDA stood at -$23.9 million in 2022, then surged by 63.02% to -$8.9 million in 2023, then soared by 101.31% to $116000.0 in 2024, then plummeted by 33835.34% to -$39.1 million in 2025.
  • The last three reported values for EBITDA were -$39.1 million (Q4 2025), -$43.9 million (Q3 2025), and -$43.1 million (Q2 2025) per Business Quant data.